secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117172
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia reports Q3 2022 net loss of $7.3M; MicroLine VISION-2 Phase 3 trial meets primary endpoint
--------------------------------------------------------------------------------

- Net loss of $7.3M ($0.21 per share) vs $5.6M loss in Q3 2021; cash $25.3M (incl. $7.9M restricted) as of Sep 30, 2022.
- VISION-2 trial achieved primary endpoint: statistically significant ≥15-letter DCNVA improvement at 2 hours; FDA meeting planned.
- Michael Rowe appointed CEO (former COO) and to Board of Directors; manufacturing facility in Redwood City, CA now operational.
- Arctic Vision Phase 3 trial of MicroLine in China enrolling patients; expects completion in late 2023.
- Collaboration with Bausch+Lomb and Optejet out-licensing progress noted; company evaluating additional partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/0001104659-22-117172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465922117172/tm2230140d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer